Published in Melanoma Res on April 01, 2010
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Changing patient perceptions of the side effects of cancer chemotherapy. Cancer (2002) 1.78
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol (2003) 1.41
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol (2009) 1.32
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol (2010) 1.31
AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol (2008) 1.28
Metastatic melanoma: chemotherapy. Semin Oncol (2002) 1.20
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12
Current and emerging targeted therapies for metastatic breast cancer. Cancer (2011) 1.08
Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol (2012) 1.06
Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol (2009) 1.04
JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer (2006) 1.03
Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer (2009) 1.02
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer (2011) 1.00
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol (2010) 1.00
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol (2010) 0.97
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer (2012) 0.96
Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol (2002) 0.96
Lung cancer in patients with HIV Infection and review of the literature. Med Oncol (2004) 0.96
Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther (2002) 0.96
Malignant melanoma. Crit Rev Oncol Hematol (2003) 0.94
Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol (2008) 0.93
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol (2007) 0.92
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer (2013) 0.90
Paving the way to the cure of melanoma. Melanoma Res (2010) 0.90
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol (2008) 0.89
Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer (2009) 0.88
Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res (2005) 0.88
[Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma]. Ann Med Interne (Paris) (2003) 0.87
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer (2011) 0.87
Retracted Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol (2011) 0.87
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol (2002) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology (2005) 0.85
Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol (2010) 0.84
Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol (2006) 0.84
Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics (2013) 0.83
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer (2013) 0.83
Accuracy of clinical data entry when using a computerized decision support system: a case study with OncoDoc2. Stud Health Technol Inform (2012) 0.83
Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study. PLoS One (2012) 0.81
Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res (2004) 0.81
Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions. Oncologist (2008) 0.81
Cetuximab plus irinotecan in refractory colorectal cancer patients. Expert Rev Anticancer Ther (2007) 0.79
Quality of life: it's never too late. J Clin Oncol (2002) 0.79
Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone (2013) 0.79
Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol (2002) 0.79
Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast (2008) 0.79
Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. Clin Cancer Res (2004) 0.79
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma. Clin Res Hepatol Gastroenterol (2013) 0.79
An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res (2006) 0.78
Ultraviolet recall dermatitis reaction with sorafenib. Invest New Drugs (2010) 0.78
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics (2015) 0.78
Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78
[Prognostic value of EGFR in colorectal cancer]. Bull Cancer (2005) 0.78
Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma: A Case Report. Medicine (Baltimore) (2015) 0.77
Leiomyosarcoma of the left atrium mimicking a left atrial myxoma. J Thorac Cardiovasc Surg (2006) 0.77
Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Bull Cancer (2005) 0.77
Temsirolimus-induced glomerulopathy. Oncology (2009) 0.77
[Neoadjuvant endocrine therapy for breast cancer: an overview]. Bull Cancer (2004) 0.77
[Protein kinases C: a new cytoplasmic target]. Bull Cancer (2008) 0.76
[Femininity and breast cancer, original approach of announcement in oncology]. Bull Cancer (2008) 0.76
[Management of brain metastases for lung cancer patients]. Bull Cancer (2013) 0.76
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol (2004) 0.76
[Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?]. Bull Cancer (2013) 0.76
Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use. J Chemother (2013) 0.75
[Gemcitabine and breast cancer]. Bull Cancer (2002) 0.75
A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy. J Clin Oncol (2009) 0.75
Are we entering a new era in melanoma treatment? Lesson from ASCO 2011. Melanoma Res (2011) 0.75
EGFR/VEGF signalling pathway in colorectal cancer: the way we are! Bull Cancer (2005) 0.75
[Strategy and management in brain metastasis]. Rev Prat (2014) 0.75
[Geriatric oncology: epidemiological evidence]. Presse Med (2009) 0.75
[Anemia and colorectal cancer]. Bull Cancer (2005) 0.75
[EGFR-targeted therapies: what's new?]. Bull Cancer (2006) 0.75